// App-Quantinova.ai

: SAFETY AND EFFICACY OF 1-MONTH VERSUS 3-MONTH DUAL ANTIPLATELET THERAPY IN HIGH BLEEDING RISK PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS WITH AN EVEROLIMUS ELUTING STENT: INSIGHTS FROM THE XIENCE SHORT DAPT PROGRAM

Researchers

Presenter

  • Marco Valgimigli

Principal Investigators

  • Davide Cao

  • Roxana Mehran

Medical Centers

  • Mount Sinai Hospital, New York, NY

  • XIENCE Short DAPT Program Investigators, Cardiocentro, Lugano, Switzerland

Locations

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

  • Central Nervous System (CNS)

Disease

  • Myocardial infarction

  • Venous thrombosis

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • Single Arm

  • Multinational

  • Multicenteric

  • Prospective

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved